CME GROUP INC.CME

CME GROUP INC. Financial Overview 2021–2025

Updated Jul 10, 2026

Driven by a record average daily volume of 28.1 million contracts, CME Group expanded its net income by 15% to $4.07 billion in FY2025. The derivatives exchange functions as a highly efficient financial toll road, successfully converting geopolitical uncertainty and interest rate volatility into persistent top-line growth and capital returns.

The company's scale and operational leverage are clear across a multi-year timeline. Total revenue steadily expanded from $4.69 billion in FY2021 to $6.52 billion in FY2025, fueled by expanding clearing and transaction fees. Beyond core trading, market data and information services grew by 13% in FY2025, proving consistent demand for its proprietary analytics. The financial engine is protected by strict expense management; even with heavy technology investments to migrate core applications to Google Cloud by Q1 2026, CME Group maintained a 69.7% operating margin in Q1 2026.

This compounding cash flow directly supports a $3.0 billion share repurchase program and an annual variable dividend framework. At the close of FY2025, the market valued the exchange's entrenched position by pricing the stock at $273.08, representing a 24.5x P/E ratio on $11.16 in full-year earnings per share.

Recent Developments (Q4 2025 and Q1 2026)

CME Group named Lynne C. Fitzpatrick as CEO, effective March 1, 2027, succeeding Terrence A. Duffy. Q1 2026 revenue reached $1.88 billion, a 14% year-over-year gain. Clearing and transaction fees totaled $1.54 billion alongside a 22% increase in total contract volume. Q1 2026 net income expanded 21% to $1.15 billion, equating to $3.18 per share. The company repurchased $539 million in stock during Q1 2026 and expanded its credit facility to a $7 billion base.

The 22% volume increase supports a bull case for transaction revenue. The bear case centers on technology and compensation costs, which pushed operating expenses up 7% to $570.4 million. The stock traded at 25.5x earnings as of April 24, 2026.

What to watch: CFO search progress; Class B shareholder voting resolutions

Rev

$6.52B

+6.4% YoY

FY2025

NI

$4.07B

+15.5% YoY

FY2025

EPS

$11.18

+15.4% YoY

FY2025

OCF

$4.28B

+15.9% YoY

FY2025

Revenue Trend
Beta

Year-over-year comparison from 10-K annual reports

View full history →

Data from SEC Company Facts

All CME Financial Metrics(55)

Recent SEC Filings

CME GROUP INC. 8-K Report, Regulation FD Disclosure (Aug 11, 2026)

CME Group Inc. (CME) filed a Form 8-K on August 11, 2026, primarily to disclose a change in its pricing structure communicated to clients through Special Executive Report No. 9799. While the specifics of the pricing adjustments are not detailed in this 8-K, the filing indicates that this information has been made available to clients and posted on the company's website. Investors should note that this filing is made under Regulation FD and is for disclosure purposes, not to trigger specific financial reporting requirements. The information provided is not deemed "filed" under the Securities Exchange Act of 1934, meaning it doesn't carry the same legal implications as other types of filings, and will not be incorporated by reference into other SEC filings unless explicitly stated.

CME GROUP INC. 8-K Report, Financial Results (Jul 22, 2026)

CME Group Inc. (CME) has filed an 8-K report on July 22, 2026, to disclose its financial results for the quarter ended June 30, 2026. The filing primarily incorporates by reference a press release (Exhibit 99.1) containing these results. Investors should note that the press release includes both GAAP (Generally Accepted Accounting Principles) and non-GAAP financial measures. While the company provides non-GAAP figures for revenues, expenses, operating income, net income, and earnings per share, it's crucial for investors to understand that these are supplemental measures and not a replacement for GAAP reporting.

CME GROUP INC. 8-K Report, Executive Changes (Jun 17, 2026)

CME Group Inc. (CME) announced a significant leadership transition, with current Chairman and CEO Terrence A. Duffy transitioning to Executive Chairman and President and CFO Lynne C. Fitzpatrick succeeding him as Chief Executive Officer. This leadership change, effective on the later of March 1, 2027, or the filing of the 2026 10-K, aims to ensure leadership continuity and leverage Duffy's extensive experience in a strategic oversight role while elevating Fitzpatrick, a long-tenured executive with deep financial and operational expertise, to lead the company. The transition plan outlines specific arrangements for both executives. Mr. Duffy will continue as CEO until the transition date and then serve as Executive Chairman through December 31, 2027, with his compensation and benefits largely remaining consistent. Ms. Fitzpatrick will assume the CEO role and a board seat on the transition date, with a new compensation package including a $1.2 million base salary, a 200% target bonus, and a 700% long-term incentive opportunity. The company has also commenced a search for Ms. Fitzpatrick's successor as CFO.

CME GROUP INC. 8-K Report, Shareholder Vote Results (Jun 10, 2026)

CME Group Inc. held its reconvened 2026 Annual Meeting of Shareholders on June 9, 2026, to vote on several proposals that were initially adjourned due to a lack of quorum among certain Class B shareholder classes. While a quorum was achieved for the combined Class A and B shares (81.36% present) and for Class B-1 and B-2 shares individually, Class B-3 shares failed to meet the 33.3% quorum requirement, preventing votes on Items 6 and 8c. Key proposals aimed at eliminating the director election rights for Class B-1 and B-2 shareholders (Items 4 and 5) did not pass, meaning these shareholders retain their rights. A proposal to amend the certificate of incorporation (Item 7) technically passed but will not be enacted due to the failure of Items 4, 5, and 6. All Class B-1 and B-2 directors seeking re-election were successful, while the election of a Class B-3 director failed to achieve quorum, resulting in a holdover director.

CME GROUP INC. 8-K Report, Shareholder Vote Results (May 19, 2026)

CME Group Inc. (CME) filed an 8-K on May 19, 2026, reporting on its 2026 Annual Meeting of Shareholders held on May 14, 2026. A significant portion of the issued and outstanding shares (87.78%) were present, establishing a quorum for Class A and Class B common stock combined. However, specific subclasses of Class B stock (B-1, B-2, B-3, and B-4) did not achieve the required 33.3% quorum, leading to the adjournment of proposals related to Items 4 through 8 to a new virtual meeting on June 9, 2026. Despite the adjournment of certain matters, the meeting did see voting on director elections, auditor ratification, and executive compensation. All director nominees were elected, the appointment of Ernst & Young LLP as the independent auditor was ratified, and the compensation of named executive officers was approved on an advisory basis. Investors should note the low participation from specific Class B shareholder groups, which necessitated the adjournment, and monitor the outcome of the rescheduled votes.

View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →